Glimstic G2

Glimstic G2 Tablet is a bilayered smart formulation combining Glimepiride 2mg and Metformin 500mg in a sustained-release form. Designed to optimize glycemic control, this dual-action oral antidiabetic therapy targets multiple mechanisms involved in type 2 diabetes management. Glimepiride, a sulfonylurea, enhances insulin secretion from pancreatic beta cells, helping reduce fasting and postprandial blood glucose levels. Metformin, a biguanide, improves insulin sensitivity and decreases hepatic glucose output. The bilayered design of Glimstic G2 allows for controlled and extended release of Metformin, ensuring better gastrointestinal tolerance and more consistent blood glucose control throughout the day. This smart tablet is ideal for patients who require a more intensive glycemic management plan without increasing the pill burden.

Some patients may experience mild side effects such as nausea, abdominal discomfort, diarrhea, or dizziness. Hypoglycemia may occur, particularly if the tablet is taken without adequate food. Rare but serious risks include lactic acidosis, especially in those with renal impairment. It is important to take this medicine exactly as prescribed and report any adverse symptoms to a healthcare provider.

Glimstic G2 Tablet is indicated for adults with type 2 diabetes mellitus when lifestyle modifications and monotherapy with either Glimepiride or Metformin do not provide sufficient glycemic control. It helps reduce both fasting and post-meal blood glucose levels.

Not recommended for patients with significant renal or hepatic impairment, heart failure, or metabolic acidosis. Caution is advised in elderly patients and during times of stress such as surgery or infection. Avoid alcohol consumption while on this medication.

Store below 30°C in a dry and cool place. Protect from direct sunlight and moisture. Keep the container tightly closed and out of the reach of children.